The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksImmupharma Share News (IMM)

Share Price Information for Immupharma (IMM)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 2.02
Bid: 1.82
Ask: 2.07
Change: 0.00 (0.00%)
Spread: 0.25 (13.736%)
Open: 2.02
High: 0.00
Low: 0.00
Prev. Close: 2.02
IMM Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

TRADING UPDATES: Enwell pleased with SV-31; SDX Energy ties in well

Fri, 06th May 2022 19:11

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Wednesday and not separately reported by Alliance News:

----------

Mpac Group PLC - Coventry, England-based packaging company - Says trading in 2022 so far has been in line with expectations. Explains the prospects pipeline is strong and its current order book is "significantly" above the previous year. However, company notes that supply chain uncertainties and operational challenges have increased, amplified by transportation delays. Mitigation measures in place and thus company remains positive. Chief Executive Tony Steels says he expects the full-year to be in line with expectations.

----------

Primorus Investments PLC - London-based investment firm focused on small and mid cap firms in financial services, technology and natural resources - Signs a deed of amendment which extends the time for investee Alteration Earth PLC to complete its prospectus and obtain its listing on the London Stock Exchange. Date has been extended to June 6 from May 4.

----------

Arix Bioscience PLC - London-based venture capital investor in biotech firms - Receives notice Acacia Research Corp that it has increased its ownership of the company. Acacia acquires a further 646,932 shares representing 21% of Arix's share capital. Acacia also notifies Arix that it does not intend to make an offer for the company.

----------

Gunsynd PLC - London-based investment company focused on the natural resources, life sciences and alcohol sector - Gives notice to Sajawin Pty Ltd to terminate the term sheet and variation terms sheet in relation to the disposal of Gunsynd's shareholding in Oyster Oil & Gas Ltd. Gunsynd, in conjunction with other shareholders in Oyster, will now seek alternative avenues to monetise the project.

----------

Pantheon Resources PLC - London-based oil and gas company focused on Alaska - Announces that the holder of its senior unsecured convertible bonds due 2026 has exercised conversion rights for USD3.8 million. Accordingly, the remaining amount under the convertible bonds will be reduced to USD46.6 million.

----------

Open Orphan PLC - London-based pharmaceutical services company - Notes market speculation regarding its potential delisting. Confirm it has no plans to delist and says it is working with Liberum Capital to complete its due diligence.

Separately, company says its subsidiary, hVIVO, has signed a "substantial" contract with an unnamed pharmaceutical client. Contract is manufacture a virus for use in human challenge studies. Adds that virus manufacturing activities have commenced and expected to be completed by the end of the third quarter of 2022. Revenue for the manufacturing process will be recognised in 2022, company says.

----------

Insig AI PLC - London-based data science and machine learning company - Signs agreement for a GBP1.0 million convertible loan note. Note provided by Non-Executive Chair Richard Bernstein. Loan is unsecured and repayable on or before December 31. An initial tranche of GBP250,000 has been drawn down.

----------

Enwell Energy PLC - London-based oil and gas company - Says SV-31 well is currently producing at a stabilised flow rate of 2.7 million standard cubic feet per day of gas and 185 barrels per day of condensate. All operations remain suspended at the Vasyschevskoye gas and condensate field and the Svystunivsko-Chervonolutskyi exploration licence in light of Russian military action in Ukraine. Chief Executive Sergii Glazunov says: "We are very pleased with the results of the SV-31 well, which was drilled safely and successfully, and ahead of schedule. The completion of the well in the current extremely challenging environment in Ukraine is a great achievement by our team, and the strong flow rates recorded will provide a welcome boost to our overall production volumes."

----------

ImmuPharma PLC - London-based drug discovery and development company - Confirms that final preparations are underway to progress Lupuzor into a new phase three trial for lupus patients. Adds that its US partner Avion Pharmaceuticals have confirmed they are requesting final guidance from the US Food & Drug Adminstration to commence the phase three trial. Chief Executive Tim McCathy says: "Following the positive readout from the [pharmacokinetic] study, we have been working closely with the team at Avion to move Lupuzor as quickly as possible to the start of the Phase 3 trial."

----------

SDX Energy PLC - London-based oil and gas company focused on Egypt and Morocco - Completes tie-in of the SD-5X Warda well one month ahead of schedule. The company holds a 37% working interest in the well. Well is now under production test, with first gas achieved on April 27. After the initial flow period, there will be a shut-in of 12 hours followed by a main flow period of five days. Post the main flow period, the well will be shut in for 10 days to monitor the pressure build-up. Chief Executive Mark Reid says: "The well is now contributing to production and cash flow from this asset much earlier than originally anticipated... Once the long-term production profile for the well has been established, we will revise our 2022 production guidance if appropriate."

----------

CleanTech Lithium PLC - Jersey-based lithium exploration and development company focused on Chile - Reports drilling at its Laguna Verde and Francisco Basin. Two drill rigs are now in operation at the Francisco Basin. Upgrades resource estimate for Laguna Verde. Maiden resource estimate for Francisco Basin on track for the second quarter of 2022. Chief Executive Aldo Boitano says: "The resource drilling programmes, which commenced in January 2022 at Laguna Verde and in March 2022 at Francisco Basin, continue to progress well. The Francisco Basin programme has been accelerated with the addition of the second rig, bringing the total number of rigs operating across both sites to three."

----------

Caerus Mineral Resources PLC - Cyprus-based exploration & resource development company focussed on Europe - Returns "consistently anomalous" gold assay results from hand auger drilling and pitting results for the Mala pyrite dump in Cyprus. Reports peak gold grades 9.9 grams per tonne of gold, 1.3 grams per tonne of gold and 1.2 grams per tonne of gold. A total of 55 auger holes and pits return gold grades from 0.1 to 9.9 grams per tonne of gold. Chief Executive Martyn Churchouse says: "The potential gold resource in the pyrite dumps combined with the known sulphide body is an excellent start and provides the confidence we need to commit to further detailed resource development."

----------

By Heather Rydings; heatherrydings@alliancenews.com

Copyright 2022 Alliance News Limited. All Rights Reserved.

More News
14 Mar 2019 10:41

ImmuPharma Preparing For Lupuzor Drug Managed Access Programme

LONDON (Alliance News) - ImmuPharma PLC said it is in final preparations to open a managed access programme for its lupus drug Lupuzor to patients in Europe.Shares in the drug discovery and

Read more
26 Feb 2019 12:06

ImmuPharma upbeat on product from subsidiary Ureka

(Sharecast News) - Specialist drug discovery and development company ImmuPharma announced on Tuesday that on 25 February, the peer reviewed research journal Nature Communications published a fundamental scientific publication on the proprietary technology 'Urelix' from its subsidiary Ureka.

Read more
31 Dec 2018 12:00

ImmuPharma and Incanthera extend exclusivity period for Nucant agreement

(Sharecast News) - Specialist drug discovery and development company ImmuPharma updated the market on its clinical development collaboration agreement for its 'Nucant' cancer programme on Monday, with specialist oncology development partner Incanthera.

Read more
7 Dec 2018 11:26

ImmuPharma Progressing To Make Lupuzor Available To Patients

LONDON (Alliance News) - ImmuPharma PLC on Friday said it is currently in the process of making Lupuzor, its drug for the treatment of lupus, available to patients via its managed access drug said

Read more
7 Dec 2018 08:09

Immupharma plots patient recruitment for Lupzor trials

(Sharecast News) - Drug discovery and development outfit Immupharma has progressed its managed access programme on Lupzor as planned, with patient recruitment in France and the UK expected to follow the firm's analysis of regulatory processes across the EU.

Read more
26 Sep 2018 13:55

ImmuPharma still banking on Lupuzor even after failed trial

(Sharecast News) - Specialist drug discovery and development company ImmuPharma announced its interim results for the six months ended 30 June on Wednesday - a period in which its revenue remained negligible at £0.07m, but its drug candidate 'Lupuzor' demonstrated a superior response rate over placebo in its primary analysis on the full set of 202 patients.

Read more
26 Sep 2018 12:53

Wednesday broker round-up

(Sharecast News) - IAG: UBS downgrades to neutral with a target price of 705p.

Read more
26 Sep 2018 12:40

ImmuPharma Interim Loss Widens On Higher Costs And Lower Revenue

LONDON (Alliance News) - ImmuPharma PLC said on Wednesday it continues to progress its lupus treatment Lupuzor, as it saw a widened loss for the first half of 2018 due to higher costs and lower a

Read more
9 Sep 2018 10:59

Sunday share tips: Immupharma, PCF Bank

(Sharecast News) - For the 'Inside the City' column in the Sunday Times, Sabah Meddings wrote a "cautionary tale" about former biotech darling Immupharma, which last year saw its shares rise 227% over a year.

Read more
7 Sep 2018 11:43

ImmuPharma Inks Pact With Incanthera For Nucant Cancer Programme

LONDON (Alliance News) - ImmuPharma PLC said Friday it signed a clinical development collaboration for the Nucant cancer programme with Incanthera Ltd, a specialist oncology development the terms

Read more
7 Sep 2018 08:10

Immupharma to make 'blockbuster' lupus treatment available

(Sharecast News) - Pharmaceutical firm ImmuPharma on Friday signed an agreement for a managed access programme (MAP) for its "ground-breaking" new lupus treatment, Lupuzor.

Read more
14 Jun 2018 12:02

Immupharma Says P140 Peptide Shows Positive Results In CIDP Treatment

LONDON (Alliance News) - ImmuPharma PLC said Thursday that its pre-clinical studies of the P140 peptide showed positive results in the treatment of chronic inflammatory demyelinating were trading

Read more
29 May 2018 09:40

ImmuPharma Excited Despite Widened Loss As Lupuzor Makes Good Results

LONDON (Alliance News) - ImmuPharma PLC said Tuesday it continues to be "excited" by its future potential despite a widened loss for 2017.The drug development company reported a a

Read more
23 Mar 2018 11:17

ImmuPharma Prepares To Report Lupuzor Study Results In April

LONDON (Alliance News) - Drug development company ImmuPharma PLC said on Friday it has been informed by Simbec-Orion that the data-base lock for the Lupuzor pivotal phase III

Read more
25 Jan 2017 14:33

ImmuPharma trial of Lupuzor continuing smoothly

(ShareCast News) - Specialist drug discovery and development company ImmuPharma provided further details of patient participation on Wednesday, following confirmation in December that the company had successfully completed patient recruitment into its pivotal 52-week Phase III clinical trial of Lupu

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.